



Editorial

Fatal Zika virus disease in adults: A critical reappraisal of an under-recognized clinical entity[☆]



Zika virus (ZIKV) is a flavivirus that was most likely introduced into Latin America back in 2013 (Rodríguez-Morales, 2015), but did not cause identifiable outbreaks until its massive emergence in Brazil in 2015, when it rapidly spread across the Americas and the Caribbean (Weaver et al., 2016). The World Health Organization (WHO) declared the ZIKV epidemic a public health emergency of international concern (PHEC) at the height of the pandemic in 2016 (Rodríguez-Morales, 2015; Rodríguez-Morales, 2018), after identifying clusters of ZIKV-associated Guillain-Barré syndrome (GBS) (do Rosario et al., 2016), and more significantly due to its association with outbreaks of microcephaly among newborn infants in which a causal link between ZIKV infection and birth defects was reliably demonstrated (Rasmussen et al., 2016). The clinical manifestations of congenital ZIKV infection extend beyond microcephaly and comprise a distinct constellation of birth defects and manifestations known as the congenital Zika syndrome (CZS) (Nogueira et al., 2018; Moore et al., 2017).

The ZIKV pandemic in the Americas and Caribbean was known to cause over one million cases and there were reports in which the virus was found to cause severe, life-threatening complications in addition to GBS and CZS, especially among patients with associated comorbidities (Rodríguez-Morales, 2018). From a clinical standpoint, until 2013, ZIKV was generally considered to cause a mild, self-limiting illness, which did not pose a serious public health threat (Rodríguez-Morales, 2015; Rodríguez-Morales, 2018; Martínez-Pulgarín et al., 2016). However, it was not until the first non-perinatal death was identified in a 15-year-old girl from northern Colombia in October 2015, (Arzuza-Ortega et al., 2016) that an increasing number of ZIKV-associated fatalities were reported in the literature.

The case from Malaysia reported by Rajahram et al. (2019) in the current issue of the *International Journal of Infectious Diseases*, confirms that ZIKV infection can result in atypical disease and lead to severe and even fatal outcomes (Rodríguez-Morales, 2018). It also demonstrates, as seen in other studies (Sarmiento-Ospina

et al., 2016; Soares et al., 2016; Zonneveld et al., 2016; Azevedo et al., 2016), that this neurotropic virus can disseminate to multiple organs and tissues, in addition to the central nervous system, while inflicting pathological effects. Previous to this report, the majority of fatalities associated with ZIKV infection were almost invariably linked to acute neurological complications (Sarmiento-Ospina et al., 2016; Soares et al., 2016; Azevedo et al., 2016). However, amongst those exceptional fatalities without neurological involvement, the question was raised as to whether ZIKV could cause renal and cardiac involvement, as was observed on autopsy examinations of the case described in this issue. Renal and cardiac complications have been reported in atypical, severe (Villamil-Gomez et al., 2016a; Alvarez et al., 2017), and fatal cases (Hoz et al., 2015; Mercado et al., 2018) of chikungunya virus (CHIKV) infection. Conversely, cases of ZIKV infection with documented renal or cardiac complications have been reported on rarely and have usually lacked detailed histopathological evaluation as well as molecular confirmation of the presence of viral RNA within the renal or cardiac tissues during routine autopsy of fatal cases (Mercado-Reyes et al., 2019).

ZIKV infection has previously been reported to cause cardiovascular compromise as a consequence of systemic infection, as revealed by electrocardiographic and echocardiographic alterations (Villamil-Gomez et al., 2018; Schwartzmann et al., 2017), even including venous thromboembolism (in ZIKV and CHIKV infections) (Ramacciotti et al., 2019), as well as demonstrating myocardial inflammation secondary to viral infection (Villamil-Gomez et al., 2018). Autopsy examinations of a heart transplant recipient who developed ZIKV infection revealed plasma cell infiltrates in the myocardial tissue, along with perivascular and endovascular damage (Schwartzmann et al., 2017).

Nevertheless, publications in the literature on cardiovascular manifestations in adult patients with ZIKV infection are scarce, and the case report by Rajahram et al. (2019) is timely in underscoring how this arboviral infection can produce unexpected clinical complications with renal and cardiovascular involvement. Previous reports have suggested an association between cardiovascular complications and ZIKV during the acute phase of the infection (Villamil-Gomez et al., 2018; Li et al., 2016; Minhas et al., 2017). However, only a limited number of studies have addressed this potential association (Martínez-Pulgarín et al., 2016; Minhas et al., 2017). Findings in patients (Abdalla et al., 2018) and non-human

[☆] The contents of this Editorial were presented in part at the 18th International Congress of Infectious Diseases (18th ICID) and the XVIII Congress of the Argentine Society for Infectious Diseases (SADI), Buenos Aires, Argentina, March 1–4, 2018 (Conference of A.J. Rodríguez-Morales at the Session 48: Zika: Regional Experiences in Neurological Diseases and Severe Cases).

primates (Li et al., 2016) have provided evidence that ZIKV has a broad tissue tropism, which includes renal and heart tissues (Rajahram et al., 2019; Li et al., 2016). Nevertheless, further investigations are needed in order to delineate the underlying pathogenic processes in which ZIKV affects myocardial tissue and to characterize the spectrum of cardiovascular manifestations caused by this emerging arboviral infection (Musso et al., 2018).

A review of the literature identified a total of 84 fatal cases of ZIKV infection during the recent pandemic in the Americas (Rodríguez-Morales et al., 2018). However, few of these reported cases underwent an in-depth tissue assessment and molecular characterization during autopsy, as was performed in the case report by Rajahram et al. (2019).

It should be emphasized that the pathogenesis of severe ZIKV infection remains poorly understood. *In vitro* and experimental animal models have provided evidence that antibody-dependent enhancement (ADE) may play a role, but clinical correlates for this phenomenon still need to be confirmed in human ZIKV infection (Ngono and Shrestha, 2018; Andrade et al., 2019). Recent studies suggested that preexisting high antibody titers to dengue virus were associated with a reduced risk of acquiring ZIKV infection and disease. In this sense, the landscape of ZIKV immunity that now exists may affect the risks of future transmission (Rodríguez-Barraguer et al., 2019). Additionally, cases with arboviral coinfections/co-detection (dengue and chikungunya) have been reported in Colombia and Brazil (Villamil-Gomez et al., 2016b; Sardi et al., 2016), as well as concurrent infections with other microorganisms such as *Leptospira* (Neaterour et al., 2017) and coinfections with other arboviruses (Mercado-Reyes et al., 2019). Circulation with other arboviruses and ADE pose a challenge for physicians and public health authorities, given the potential to confound and delay diagnosis and possibly influence poorer outcomes in patients with previous exposure to other flaviviruses (Ngono and Shrestha, 2018). As a result, multiple research networks on ZIKV and arboviruses in general have been established, which can leverage protocols, methodologies, and multidisciplinary approaches to inform treatment, prevention, and control strategies. Although recent advances have greatly contributed to our understanding of ZIKV pathogenesis, systemic involvement and the expanding tissue tropism of this virus and its potential relationship to different lineages highlight important aspects for future investigation. Finally, it is worth considering the setting for vaccine development and preparedness for other emerging arboviruses in Latin America and the Asia-Pacific region, such as Ross River, Mayaro, Oropouche, Madariaga, West Nile, and the Venezuelan equine encephalitis and Eastern equine encephalitis viruses.

Financial support

None.

Conflict of interest

All authors report no potential conflicts. All authors have submitted the ICMJE Disclosure Form for Potential Conflicts of Interest.

Author contributions

AJRM conceived the idea of the Editorial and performed a review of the literature on the related topic. All authors read the case that is being editorialized. AJRM developed the first draft of the manuscript. All authors consequently contributed to revisions. All authors approved the final version submitted.

Acknowledgements

This article was presented in part at the 18th International Congress of Infectious Diseases (18th ICID) and the XVIII Congress of the Argentine Society for Infectious Diseases (SADI), Buenos Aires, Argentina, March 1–4, 2018 (Conference of A.J. Rodríguez-Morales at Session 48: Zika: Regional Experiences in Neurological Diseases and Severe Cases). The Faculty of Health Sciences of the Universidad Tecnológica de Pereira, the Colombian Association of Infectious Diseases (ACIN) (Coffee-Triangle Region chapter), and the International Society for Infectious Disease (ISID) supported A. J. Rodríguez-Morales in his participation at the ICID/SADI meetings where this article was initially presented.

References

- Abdalla LF, Santos JHA, Barreto RTJ, Souza EME, D'Assuncao FF, Borges MA, et al. Atrial fibrillation in a patient with Zika virus infection. *Viol J* 2018;15:23.
- Alvarez MF, Bolivar-Mejia A, Rodriguez-Morales AJ, Ramirez-Vallejo E. Cardiovascular involvement and manifestations of systemic Chikungunya virus infection: a systematic review. *F1000Res* 2017;6:390.
- Andrade P, Gimblet-Ochieng C, Modirian F, Collins M, Cardenas M, Katelnick LC, et al. Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika. *Nat Commun* 2019;10:938.
- Arzuza-Ortega L, Polo A, Perez-Tatis G, Lopez-Garcia H, Parra E, Pardo-Herrera LC, et al. Fatal sickle cell disease and Zika virus infection in girl from Colombia. *Emerg Infect Dis* 2016;22:925–7.
- Azevedo RS, Araujo MT, Martins Filho AJ, Oliveira CS, Nunes BT, Cruz AC, et al. Zika virus epidemic in Brazil. I. Fatal disease in adults: clinical and laboratorial aspects. *J Clin Virol* 2016;85:56–64.
- do Rosario MS, de Jesus PA, Vasilakis N, Farias DS, Novaes MA, Rodrigues SG, et al. Guillain-Barre syndrome after Zika virus infection in Brazil. *Am J Trop Med Hyg* 2016;95:1157–60.
- Hoz JM, Bayona B, Viloria S, Accini JL, Juan-Vergara HS, Viasus D. Fatal cases of Chikungunya virus infection in Colombia: diagnostic and treatment challenges. *J Clin Virol* 2015;69:27–9.
- Li XF, Dong HL, Huang XY, Qiu YF, Wang HJ, Deng YQ, et al. Characterization of a 2016 clinical isolate of Zika virus in non-human primates. *EBioMedicine* 2016;170–7.
- Martinez-Pulgarin DF, Acevedo-Mendoza WF, Cardona-Ospina JA, Rodriguez-Morales AJ, Paniz-Mondolfi AE. A bibliometric analysis of global Zika research. *Travel Med Infect Dis* 2016;14:55–7.
- Mercado M, Acosta-Reyes J, Parra E, Guzman L, Beltran M, Gasque P, et al. Renal involvement in fatal cases of Chikungunya virus infection. *J Clin Virol* 2018;103:16–8.
- Mercado-Reyes M, Acosta-Reyes J, Navarro-Lechuga E, Corchuelo S, Rico A, Parra E, et al. Dengue, Chikungunya and Zika virus coinfection: results of the national surveillance during the Zika epidemic in Colombia. *Epidemiol Infect* 2019;147:e77.
- Minhas AM, Nayab A, Iyer S, Narmeen M, Fatima K, Khan MS, et al. Association of Zika virus with myocarditis, heart failure, and arrhythmias: a literature review. *Cureus* 2017;9:e1399.
- Moore CA, Staples JE, Dobyns WB, Pessoa A, Ventura CV, Fonseca EB, et al. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. *JAMA Pediatr* 2017;171:288–95.
- Musso D, Rodriguez-Morales AJ, Levi JE, Cao-Lormeau VM, Gubler DJ. Unexpected outbreaks of arbovirus infections: lessons learned from the Pacific and tropical America. *Lancet Infect Dis* 2018;18:e355–61.
- Neaterour P, Rivera A, Galloway RL, Negron MG, Rivera-Garcia B, Sharp TM. Fatal *Leptospira* spp./Zika virus coinfection-Puerto Rico, 2016. *Am J Trop Med Hyg* 2017;97:1085–7.
- Ngono AE, Shrestha S. Immune response to dengue and Zika. *Annu Rev Immunol* 2018;36:279–308.
- Nogueira ML, Nery [189_TD\$DIFF]Junior NRR, Estofolete CF, Bernardes Terzian AC, Guimaraes GF, Zini N, et al. Adverse birth outcomes associated with Zika virus exposure during pregnancy in Sao Jose do Rio Preto, Brazil. *Clin Microbiol Infect* 2018;24:646–52.
- Rajahram GS, Hale G, Bhatnagar J, Hiu J, Thayan R, William T, et al. Postmortem evidence of disseminated Zika virus infection in an adult patient. *Int J Infect Dis* 2019;. doi:http://dx.doi.org/10.1016/j.ijid.2019.01.047.
- Ramacciotti E, Agati LB, Aguiar VCR, Wolosker N, Guerra JC, de Almeida RP, et al. Zika and Chikungunya virus and risk for venous thromboembolism. *Clin Appl Thromb Hemost* 2019;25:.
- Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects—reviewing the evidence for causality. *N Engl J Med* 2016;374:1981–7.
- Rodriguez-Barraguer I, Costa F, Nascimento EJM, Nery NJ, Castanha PMS, Sacramento GA, et al. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. *Science* 2019;363:607–10.
- Rodriguez-Morales AJ, Acevedo-Mendoza WF, Nasner-Posso KM, Martinez-Pulgarin DF, Restrepo-López A, Cardona-Ospina JA. Postnatal acquired fatal Zika virus infection in the Americas: a systematic review. *Int J Infect Dis* 2018;73:195.

- Rodriguez-Morales AJ. Zika: the new arbovirus threat for Latin America. *J Infect Dev Ctries* 2015;9:684–5.
- Rodriguez-Morales AJ. Severe, atypical and fatal cases of Zika virus infection: experience in Colombia. *Int J Infect Dis* 2018;73:71.
- Sardi SI, Somasekar S, Naccache SN, Bandeira AC, Tauro LB, Campos GS, et al. Coinfections of Zika and Chikungunya viruses in Bahia, Brazil, identified by metagenomic next-generation sequencing. *J Clin Microbiol* 2016;54:2348–53.
- Sarmiento-Ospina A, Vasquez-Serna H, Jimenez-Canizales CE, Villamil-Gomez WE, Rodriguez-Morales AJ. Zika virus associated deaths in Colombia. *Lancet Infect Dis* 2016;16:523–4.
- Schwartzmann PV, Ramalho LN, Neder L, Vilar FC, Ayub-Ferreira SM, Romeiro MF, et al. Zika virus meningoencephalitis in an immunocompromised patient. *Mayo Clin Proc* 2017;92:460–6.
- Soares CN, Brasil P, Carrera RM, Sequeira P, de Filippis AB, Borges VA, et al. Fatal encephalitis associated with Zika virus infection in an adult. *J Clin Virol* 2016;83:63–5.
- Villamil-Gomez WE, Ramirez-Vallejo E, Cardona-Ospina JA, Silvera LA, Rodriguez-Morales AJ. Electrocardiographic alterations in patients with chikungunya fever from Sucre, Colombia: a 42-case series. *Travel Med Infect Dis* 2016a;14:510–2.
- Villamil-Gomez WE, Rodriguez-Morales AJ, Uribe-Garcia AM, Gonzalez-Arismendy E, Castellanos JE, Calvo EP, et al. Zika, dengue, and chikungunya co-infection in a pregnant woman from Colombia. *Int J Infect Dis* 2016b;51:135–8.
- Villamil-Gomez WE, Ramirez-Vallejo E, Rodriguez-Morales AJ. Cardiac compromise in Zika virus infection. *Mayo Clin Proc* 2018;93:393–4.
- Weaver SC, Costa F, Garcia-Blanco MA, Ko AI, Ribeiro GS, Saade G, et al. Zika virus: history, emergence, biology, and prospects for control. *Antiviral Res* 2016;130:69–80.
- Zonneveld R, Roosblad J, Staveren JW, Wilschut JC, Vreden SG, Codrington J. Three atypical lethal cases associated with acute Zika virus infection in Suriname. *IDCases* 2016;5:49–53.

Alfonso J. Rodríguez-Morales^{a,b,*}

^aPublic Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia

^bColombian Collaborative Network of Zika (RECOLZIKA), Pereira, Risaralda, Colombia

Eduardo Ramírez-Vallejo^{a,b,c}

^aPublic Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia

^bColombian Collaborative Network of Zika (RECOLZIKA), Pereira, Risaralda, Colombia

^cEduardo Ramirez Vallejo Cardiología SAS, Pereira, Risaralda, Colombia

Lucia Elena Alvarado-Arnez

National Research Coordination, Universidad Franz Tamayo/UNI-FRANZ, Cochabamba, Bolivia

Alberto Paniz-Mondolfi^{a,b,c,d,e}

^aColombian Collaborative Network of Zika (RECOLZIKA), Pereira, Risaralda, Colombia

^bDepartment of Infectious Diseases and Tropical Medicine, Clínica IDB Cabudare, Instituto de Investigaciones Biomédicas IDB, Barquisimeto, 3023, Lara, Venezuela

^cInfectious Diseases Research Branch, Venezuelan Science Incubator and the Zoonosis and Emerging Pathogens Regional Collaborative Network, Cabudare, 3023, Lara, Venezuela

^dLaboratorio de Señalización Celular y Bioquímica de Parásitos, Instituto de Estudios Avanzados (IDEA), Caracas, Venezuela

^eAcademia Nacional de Medicina, Caracas, Venezuela

Lysien I. Zambrano^{a,b,c}

^aColombian Collaborative Network of Zika (RECOLZIKA), Pereira, Risaralda, Colombia

^bDepartment of Morphological Sciences, School of Medical Sciences, Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras

^cCardiovascular Division, Department of Physiology, Escola Paulista de Medicina (UNIFESP-EPM), Universidade Federal de São Paulo, São Paulo, Brazil

Albert I. Ko^{a,b}

^aDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

^bInstituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Bahia, Brazil

* Corresponding author at: Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia.
E-mail address: arodriguezm@utp.edu.co (A. Rodríguez-Morales).

Corresponding Editor: Eskild Petersen, Aarhus, Denmark

Received 3 March 2019